Cambridge Investment Research Advisors
CRMD icon

Cambridge Investment Research Advisors’s CorMedix CRMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,700
Closed -$49K – 3186
2021
Q4 		$49K Sell
10,700
-8,000
-43% -$39.7K ﹤0.01% 3101
2021
Q3 		$87K Hold
18,700
– – ﹤0.01% 2972
2021
Q2 		$128K Buy
+18,700
New +$149K ﹤0.01% 2931

Other funds holding CRMD

Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambridge Investment Research Advisors's CRMD Position: Q1 2022 in Review

Cambridge Investment Research Advisors sold out of CorMedix (CRMD) in Q1 2022, closing a stake of 10,700 shares — an estimated $49K sold.

Cambridge Investment Research Advisors first reported a position in CRMD in Q2 2021 and held it in 3 quarters. The position peaked at $128K in Q2 2021. 85 funds tracked by Wall St. Rank hold CRMD as of Q1 2022.

  • Cambridge Investment Research Advisors reported no remaining CorMedix position as of Q1 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,700 CorMedix shares in Q1 2022, an estimated $49K.
  • Cambridge Investment Research Advisors first reported a position in CorMedix in Q2 2021 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's CorMedix position peaked at $128K in Q2 2021.
  • 85 funds tracked by Wall St. Rank held CorMedix as of Q1 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2022, filed 12 May 2022.